Sen. Grassley Seeks FDA Documents On Vioxx Labeling Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
Senate Finance Committee chair questions why FDA did not adopt recommendations by a cardio-renal division medical officer that a cardiovascular warning be added to Vioxx labeling. Grassley calls FDA’s drug safety initiative “welcome, albeit late in coming.”
You may also be interested in...
House Energy & Commerce Committee Opens Vioxx Investigation
The House Energy & Commerce Committee has opened its investigation into the withdrawal of Vioxx with letters to FDA and Merck
House Energy & Commerce Committee Opens Vioxx Investigation
The House Energy & Commerce Committee has opened its investigation into the withdrawal of Vioxx with letters to FDA and Merck
Senate Vioxx Hearing To Include Merck’s Gilmartin, FDA’s Crawford
A Nov. 18 Senate Finance Committee hearing on the withdrawal of Vioxx will include testimony from Merck CEO Ray Gilmartin